Presentation is loading. Please wait.

Presentation is loading. Please wait.

Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Influenza Vaccination and Vitamin K Antagonist Treatment:

Similar presentations


Presentation on theme: "Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Influenza Vaccination and Vitamin K Antagonist Treatment:"— Presentation transcript:

1 Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Influenza Vaccination and Vitamin K Antagonist Treatment: A Placebo-Controlled, Randomized, Double- blind Crossover Study Arch Intern Med. 2010;170(7):609-616. doi:10.1001/archinternmed.2010.49 Flowchart (A) and design (B) of the study. In B, white rectangles indicate vaccine-placebo sequence; grey rectangles, placebo- vaccine sequence. INR indicates international normalized ratio; T, time; and VKA, vitamin K antagonist. Figure Legend:

2 Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Influenza Vaccination and Vitamin K Antagonist Treatment: A Placebo-Controlled, Randomized, Double- blind Crossover Study Arch Intern Med. 2010;170(7):609-616. doi:10.1001/archinternmed.2010.49 Correlation between capillary and venous international normalized ratios (INRs). A, Shows the outcome of Passing regression. B, Shows the Bland procedure. In B, the distance between the solid line and the equivalence line (that crosses the y-axis at 0) is a measure of bias, while the dashed lines indicate the limits of agreement as calculated using Bland-Altman plot analysis. Figure Legend:

3 Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Influenza Vaccination and Vitamin K Antagonist Treatment: A Placebo-Controlled, Randomized, Double- blind Crossover Study Arch Intern Med. 2010;170(7):609-616. doi:10.1001/archinternmed.2010.49 Weekly courses of international normalized ratios (INRs) (A), warfarin sodium doses (B), and percentages of time spent in therapeutic range (C). A and B, Patients in VP (vaccine-placebo) and PV (placebo-vaccine) sequences. C, Mean results among all patients after summing up sequence groups across the crossover. Figure Legend:

4 Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Influenza Vaccination and Vitamin K Antagonist Treatment: A Placebo-Controlled, Randomized, Double- blind Crossover Study Arch Intern Med. 2010;170(7):609-616. doi:10.1001/archinternmed.2010.49 Individual response profiles for international normalized ratio (INR) (A) and warfarin sodium weekly dose (B) as estimated using the mixed-effects model of analysis of variance. No trend is evident on visual inspection. Figure Legend:


Download ppt "Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Influenza Vaccination and Vitamin K Antagonist Treatment:"

Similar presentations


Ads by Google